p38γ, active, GST tagged human
SIGMA/G8546 - PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
Synonym: ERK3; ERK6; MAPK12; PRKM12; SAPK3
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| mol wt | ~71 kDa |
| product line | PRECISIO® Kinase |
| Quality Level | 200  |
| recombinant | expressed in baculovirus infected Sf9 cells |
| shipped in | dry ice |
| specific activity | 56-76 nmol/min·mg |
| storage temp. | −70°C |
| UniProt accession no. | P53778  |
| Biochem/physiol Actions: | p38γ is a key protein of the MAPK (mitogen-activated protein kinase) pathway and is involved in cell differentiation, growth, cycle and apoptosis and inflammation. It is essential for normal localization of polo-like kinase 1 (Plk1) at the kinetochore. This protein facilitates mitotic cell viability and suppresses chromosomal instability. Studies suggest that this protein negatively controls the expression of GLUT4 (glucose transporter) and the uptake of glucose mediated by contraction in adult skeletal muscles. |
| General description: | p38γ, commonly known as MAPK12 (mitogen-activated protein kinase 12), is one of the four isoforms of the p38 MAPK family. This isoform shows predominant expression in skeletal muscle and is controlled by exercise. |
| Legal Information: | PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Physical form: | Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥70% (SDS-PAGE) |
| activity | specific activity: 56-76 nmol/min·mg |
| Storage Temp. | −70°C |
| UNSPSC | 51111800 |